Clinical trial
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated…
NCT00097487 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00097487 |
|---|---|
| Title | A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane |
| Official title | Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Breast Cancer, Metastases |
| Enrollment | 1,000 |
| Start date | Nov 30, 2000 |
| Completion | Sep 30, 2004 |
| First posted | Nov 25, 2004 |
| Last update posted | Mar 2, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: